Study Purpose: This research is testing the safety of a new medicine called sotorasib. It is for adults with a specific type of cancer with a KRAS p.G12C mutation, which means there is a small change in their cancer cells that the drug may target.
Who Can Join: People who are 18 years or older and have advanced or metastatic (spread to other parts of the body) cancer with the KRAS p.G12C mutation. This mutation must be confirmed by a special lab test. However, people with certain brain conditions or heart issues cannot join.
- Time Commitment: Participants will be involved in the study for an undetermined period, which includes regular visits for check-ups.
- Health Considerations: This trial is not suitable for those with primary brain tumors or recent heart attacks.
- Compensation: Details on compensation for participation are not provided.